This observational study is looking at how giving high doses of vitamin D3 affects young people (ages 5-25) with inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis. You could be eligible if you are already receiving biologic treatments like Infliximab or Vedolizumab every 4-8 weeks and have low vitamin D levels (less than 40 ng/mL). The researchers will give you oral high-dose vitamin D3 at the same time as your biologic treatment. The main goal is to see if participants reach a target vitamin D level by the end of the study, which could be up to 64 weeks. The current status of this study is unclear, and it plans to enroll 50 participants.

Study design

This is an observational study with a planned enrollment of 50 participants. It is not specified if it is randomized or blinded.

What's involved

You will receive oral high-dose vitamin D3 concurrently with your regular biologic treatment every 4-8 weeks. Additional bloodwork and questionnaires will be collected during your infusion visits.

Compensation

Not stated in the trial record.

Follow-up

Your vitamin D levels will be measured at the study's conclusion, which can be up to 64 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.